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Two closely related genes, the presenilins (PS), located
at chromosomes 14q24.3 and 1q42.1, have been identi-
fied for autosomal dominant Alzheimer disease (AD) with
onset age below 65 years (presenile AD). We performed
a systematic mutation analysis of all coding and 5′-non-
coding exons of PS-1 and PS-2 in a population-based
epidemiological series of 101 unrelated familial and spor-
adic presenile AD cases. The familial cases included 10
patients of autosomal dominant AD families sampled for
linkage analysis studies. In all patients mutations in the
amyloid precursor protein gene (APP) had previously
been excluded. Four different PS-1 missense mutations
were identified in six familial cases, two of which where
autosomal dominant cases. Three mutations resulted in
onset ages above 55 years, with one segregating in an
autosomal dominant family with mean onset age 64
years (range 50–78 years). One PS-2 mutation was identi-
fied in a sporadic case with onset age 62 years. Our
mutation data provided estimates for PS-1 and PS-2
mutation frequencies in presenile AD of 6 and 1% re-
spectively. When family history was accounted for muta-
tion frequencies for PS-1 were 9% in familial cases and
18% in autosomal dominant cases. Further, polymorph-
isms were detected in the promoter and the 5′-non-cod-
ing region of PS-1 and in intronic and exonic sequences
of PS-2 that will be useful in genetic association studies.
INTRODUCTION
Alzheimer disease (AD) is the most common cause of senile
dementia and the fourth leading cause of death in western
societies. AD is a neurodegenerative disorder of the central
nervous system characterized by progressive loss of memory and
intellectual functioning due to the appearance in the brain of two
major lesions: senile plaques and neurofibrillary tangles. The
exact biochemical pathway leading to neurodegeneration is still
unknown. In most AD cases the first symptoms of memory
dysfunction or behavior changes become apparent after age 65
years (late-onset or senile AD); however, in many cases the
disease starts earlier in life (early-onset or presenile AD). There
are no indications that the disease in presenile AD cases is
different from that observed in senile AD cases, apart from a more
severe pathology and more rapid clinical progression. Both senile
and presenile AD have a genetic etiology; however, genetic cases
are more frequent among presenile AD cases (for a review see 1).
Also, several AD families have been documented that segregate
presenile AD in an autosomal dominant manner. In these families
a positional cloning approach has been employed to identify AD
genes (for a review see 1). To date, three AD genes are known
that, when mutated, lead to presenile AD: the amyloid precursor
protein gene (APP) on chromosome 21 at 21q21.1 (2); the
presenilin-1 gene (PS-1) on chromosome 14 at 14q24.3(3); the
presenilin-2 gene (PS-2) on chromosome 1 at 1q42.1 (4,5).
Although the normal function of the amyloid precursor protein
(app) is unknown, mutations have been demonstrated to alter
endoproteolysis of app such that more of a 42 amino acid long
form of amyloid β (Aβ42) is produced (6). Rapid deposition of
Aβ42 in AD brains is an early morphological event in AD
pathology. Also, the normal and pathological functions of the
presenilin proteins (ps-1 and ps-2) are unknown (for a review see
7). Since they both constitute integral membrane proteins with six
to eight transmembrane domains (TM) and one large hydrophilic
loop (HL) (8,9), similar functions of ps-1 and ps-2 were
predicted. Remarkably, mutations in PS-1 and PS-2 also produce
more Aβ42, suggesting that PS mutations and APP mutations
lead to AD pathology through a common biochemical pathway.
In APP seven different mutations have been identified in
autosomal dominant families with presenile AD or AD-related
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phenotypes (6). All mutations occur in exons 16 and 17, encoding
the Aβ proteolysis product of app. However, extensive mutation
analyses have shown that mutations in APP are rare, since they
segregate in only 5% of the presenile AD families (1). Since the
PS genes were identified more recently (for a review see 7),
extensive mutation analyses have not yet been performed.
However, initial estimates based on linkage analysis studies
suggested that 70% of the presenile AD families were linked to
chromosome 14 (10). Later, a mutation in PS-1 was found in each
chromosome 14-linked AD family (3,11,12). To date 42 different
missense mutations and one in-frame splice site mutation in PS-1
have been reported in 82 families world wide (13). Mutation
screenings of PS-1 in presenile AD families not selected on the
basis of linkage to chromosome 14 indicated that PS-1 mutations
contribute less (30–50%) than initially estimated (14,15). A
possible explanation for the lower mutation frequency of PS-1
may be that the initial mutation data were biased towards finding
PS-1 mutations, since most families analyzed had been included
in a genome-wide search for AD genes and were known to be
linked to chromosome 14. Only one mutation has been reported
in a proven non-familial AD case (16); however, only few
mutation studies of sporadic AD cases have been performed.
Initial linkage studies indicated that PS-2 mutations are far less
frequent than PS-1 mutations (5). Apart from the one PS-2
mutation identified in the chromosome 1-linked group of Volga
German AD families, only one other PS-2 mutation has been
identified to date (5,17). However, in contrast to PS-1 families
onset ages in PS-2 families are highly variable and usually later
in life (13). Therefore, it cannot be excluded that PS-2 families
may have been missed, since presenile AD families with earlier
onset ages are more likely to be ascertained for linkage analysis
studies since they have more clear inheritance patterns. To date no
mutation reports of PS-2 in non-familial presenile AD cases have
been published; however, PS-2 has been less intensively investi-
gated for mutations than PS-1.
In this study we aimed at evaluating the genetic contributions
of PS-1 and PS-2 mutations to presenile AD in autosomal
dominant, familial and sporadic cases. To overcome several of the
biases mentioned above we used a unique sample of 101
unrelated familial and sporadic presenile AD cases ascertained in
a population-based manner in The Netherlands (18,19). The
sample contained 11 autosomal dominant, 56 familial and 34
sporadic presenile AD cases. The mean onset age was 56.7 ± 5.4
years (range 45–64 years), being lower than 60 years in 71 cases
and lower than 50 years in 10 cases. In the autosomal dominant
AD families all probands had an onset age before 65 years;
however, in four families the mean onset age was above 65 years.
In addition we analyzed the families of 10 autosomal dominant
presenile AD cases included in this population-based study (20).
In all cases mutations in exons 16 and 17 of the APP gene were
previously excluded (19,20) while one family was shown to be
linked to chromosome 14 (20).
Table 1. Intronic PCR primers flanking the coding and 5′-non-coding exons of PS-1 and PS-2
PS-1 PS-2
Exon Primer Sequence Size (bp) Exon Primer Sequence Size (bp)
1A S182ex1A-3 TTCTCCCCGCAATCGTTTCTCCAG 297 1 PS-2ex1-3 TGTTAGCAGCGGTGTTTG 248
S182ex1A-4 GCCCATGTCCGCGGTGCCTTCC PS-2ex1-4 TCTGCTCGGAGGGATGGAC
1B S182ex1B-3 AGGAGGGGCGGCCCGTTTCTCG 523 2 PS-2ex2-1 CAGGGCCAGGGGGAGGAA 303
S182ex1B-4 AGCCTCTGCCACCACCGNAGGATC PS-2ex2-2 AAAAGCAGGTTGGGAGTCAC
2 S182ex2-3 TGGATGACCTGGTGAAATCCTATT 223 3 PS-2ex3-1 GTCCTCCACTGCCTTTGTCTCAC 328
S182ex2–4 CAGAAAACAAAGCCTCTTGAGGTT PS-2ex3–2 CTTCCCTTCTCCCTCCCGCATCAG
3 S182ex3-1 ACAAAGTTCTGTTTTTCTTTCCC 247 4 52PS-2x4 AAAAATCCGTGCATTACAT 395
S182ex3-2 CAGCATTTCTCAGAGGTGAGG 3PS-2x4 GCTGGTTGTGAGCTGCAGGTACAGTG
4 S182ex4-1 CGTTACCTTGATTCTGCTGA 371 5 PS-2-ex5-1 AGCCTCGAGGAGCAGTCAG 241
S182ex4-2 GACATGCTGTAAAGAAAAGCC PS-2-ex5–2 GCAGACGGAGAGAAGCGT
5 S182ex5-3 GATTGGTGAGTTGGGGAAAAGTG 335 6 5PS-2x6 GGTATCAGTCTCAGGATCATGGG 265
S182ex5-4 ATACCCAACCATAAGAAGAACAGG 3PS-2x6 TGGGGAAGACTGGAGCTCGATG
6 S182ex6-3 GGTTGTGGGACCTGTTAATT 149 7 PS-2-ex7-1 GTAAAGAGGGCCAGGTTGGG 387
S182ex6-4 TTAATTCTGAAAGACAGACCC PS-2-ex7-2 GTGCAGCACTGGGGACGATTT
7 S182ex7-1 GGAGCCATCACATTATTCTAAA 326 8 52PS-2x8 GGGCAGGCTCTTCTTCAGGG 251
S182ex7-2 AACAAATTATCAGTCTTGGGTTT 3PS-2x8 GAAAGCCACGGCCAGGAAG
8 S182ex8-1 TTACAAGTTTAGCCCATACATTTT 215 9 PS-2ex9–3 ACCGCCTGAGACGTGAACCTT 235
S182ex8-2 TCAAGTTCCCGATAAATTCTAC PS-2ex9–4 TCCCTCTGCCCCTCCTGAACT
9 S182ex9-1 TGTGTGTCCAGTGCTTACCTG 188 10 5PS-2x10 CTCTGACCAGCTGTTGTTTC 249
S182ex9-2 TGTTAGCTTATAACAGTGACCCTG 3PS-2x10 AGCCTCCACCCTCTGTCT
10 S182ex10-1 CCAGCTAGTTACAATGACAGC 345 11 5PS-2x11 TTCCATTCTGTGCACGCCTC 244
S182ex10-2 TCAAAAAGGTTGATAATGTAGCT 3PS-2x11 ACCTGCCCCCACCACAATG
11 S182ex11-1 GGTTGAGTAGGGCAGTGATA 275 12 PS-2ex12-3 ACACCAGGGATCACCACGCTCAC 344
S182ex11-2 TTAAAGGGACTGTGTAATCAAAG PS-2ex12–4 TGCCTCCTCCTCACCAAGTAAACA
12 S182ex12-1 GTCTTTCCCATCTTCTCCAC 199
S182ex12-2 GGGATTCTAACCGCAAATAT
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Table 2. Missense mutations detected in PS-1 and PS-2
Gene Exon Location Mutation Family Onset  age (years) Family historya Restriction site change
PS-1 4 236C→T Ala79Val 1005 53 AD AciI, BbeI, BanI, EheI, HaeII, HinP1I,
HhaI, Hsp92I, KasI, NarI, NlaIV
1087 55 F
1061 58 F
5 344A→G Tyr115Cys 1066 45 AD Csp6I, RsaI
7 692C→T Ala231Val 1072 58 F BglI, Bsp1286I, MwoI
9 953A→G Glu318Gly 1069 57 F
PS-2 4 185G→A Arg62His 1121 62 S AciI
aAD, autosomal dominant; F, familial; S, sporadic.
Nucleotide positions are relative to the translation start site in the PS-1 or PS-2 cDNA. Restriction enzymes used in this study to test for the presence of the mutation
are denoted in bold (Fig. 1A). The pedigrees of families with a PS-1 mutation are depicted in Figure 2.
Table 3. Polymorphisms detected in PS-1 and PS-2
Gene Exon Location Codon Allele frequencies Restriction site change
PS-1 1A (–48)C→T 0.88/0.12 HgaI, Hsp96I, SfaNI
1B –364C→A 0.18/0.82 BstXI
8 (+16)A→C 0.54/0.46 Alw26I
PS-2 3 69C→T Ala23 0.79/0.21 DdeI
3 129C→T Asn43 n.d. TspRI
4 (–42)A→G 0.54/0.46 NcoI, NlaIII, StyI
4 261C→T His87 0.46/0.54 BbrPI, BsaAI, Eco72I, MaeII, NlaIII, NspI, TaiI
5 366G→A Thr122 n.d.
7 708T→C Ser236 n.d. BssHII, BstUI, Cag8I, HinPI, TspRI
11 (+24)A→G 0.55/0.45 AluI, Bst71I, BstF5I, CviJI, MspA1I, PvuII
The nucleotide position of exonic polymorphisms are relative to the translation start site in the PS-1 or PS-2 cDNA. The nucleotide positions of intronic polymorph-
isms are relative to the start (+) or end (–) of the intron. Allele frequencies were determined in the 118 control individuals using the restriction enzymes denoted in
bold (Fig. 1B). n.d., not determined.
RESULTS
Mutation analysis of PS-1 and PS-2
Previously, the complete genomic structure of PS-1 and PS-2 was
determined identifying 10 coding exons in each gene (21,22). In
order to avoid confusion we used the exon numbering 3–12 for
PS-1 in this study, as introduced by Clark et al. (11). Intronic
primer pairs were designed allowing PCR amplification of the 10
coding exons of PS-1 and PS-2 (Table 1). All 101 AD patients
were examined for mutations in PS-1 and PS-2 by SSCP analysis
and PCR cycle sequencing.
In PS-1 we identified four missense mutations in exons 4, 5, 7
and 9 respectively and one intronic polymorphism in intron 8
(Tables 2 and 3 and Fig. 1). The Ala79Val mutation was identified
in three patients (1005, 1061 and 1087) (Table 2). To test whether
the mutation in the three patients has the same ancestral origin we
genotyped three simple tandem repeat (STR) markers flanking
PS-1 (23,24). For D14S1028, D14S77 and D14S1004 all patients
shared one common allele with allele frequencies calculated
among the cases of respectively 0.27, 0.05 and 0.12. These data
suggested that the three patients carrying the Ala79Val mutation
might be related, although not closely, since genealogy studies
had not indicated a familial relationship. The other three
mutations occurred only once and none of the mutations were
present in the 118 control individuals. The polymorphism
observed in intron 8 is identical to that reported by Wragg et al.
(25) and allele frequencies were determined by the primer
mismatch PCR assay described by those authors (Table 3). Since
the SSCP pattern of the intron 8 polymorphism could have
masked the presence of mutations, we sequenced exon 8 in all
cases. No other mutations were found.
In one patient a missense mutation in PS-2 was detected,
resulting in an Arg→His substitution at codon 62 in exon 4 (Table
2 and Fig. 1A). Restriction digestion analysis showed that the
mutation was absent in the other patients and controls. In addition,
SSCP and sequence analysis of exon 4 identified two different
polymorphisms in intron 3 and at codon His87 respectively
(Table 3). Also, the SSCP patterns observed for exons 3, 5, 7 and
11 were due to polymorphisms, since the nucleotide changes
involved intronic variations or exonic silent mutations (Table 3
and Fig. 1B). The polymorphism in exon 5 (Thr122) was seen in
only one patient and represents a very rare polymorphism. Also,
the polymorphism in exon 7 (Ser236) is rare, since it was seen in
only two patients. The allele frequencies of the other more
frequent polymorphisms were estimated in the 118 control
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Figure 1. Restriction enzyme analyses of mutations and polymorphisms in PS-1 and PS-2. PCR amplified exons were digested with the restriction enzymes indicated.
(A) Missense mutations in PS-1 and PS-2. (B) Polymorphisms in PS-1 and PS-2.
individuals by restriction enzyme digestion (Table 3). Compari-
son of the allele distribution in 15 control individuals showed that
the two exon 3 polymorphisms are in linkage disequilibrium.
Also, the two exon 4 polymorphisms are in linkage disequilib-
rium. Further, we demonstrated that the PS-2 polymorphisms in
exons 3 (Ala23) and 4 (His87) and intron 11 show Mendelian
inheritance.
To complete the mutation analysis of PS-1 and PS-2 we
developed flanking primers for the three exons located in the
5′-untranslated region (5′-UTR) of PS-1 (numbered exons 1A, 1B
and 2) and the two 5′-UTR of PS-2 (21,26). SSCP analysis
followed by PCR cycle sequencing revealed two polymorphisms
in the 5′-UTR of PS-1, but no mutations (Table 3). Allele
frequencies of both polymorphisms were estimated by SSCP
analysis of exon 1A and restriction digestion of exon 1B (Table 3
and Fig. 1B). Mendelian inheritance of both polymorphisms was
demonstrated. No mutations or polymorphisms were detected in
the 5′-UTR of PS-2.
Although SSCP analysis of PS-1 and PS-2 was negative in
eight of the 10 autosomal dominant probands included in our
sample, we could not rule out that mutations may have been
missed, since the sensitivity of SSCP is not 100%. Therefore, we
performed a mutation analysis of PS-1 and PS-2 cDNA
synthesized from RNA isolated from cultured lymphoblasts of a
47
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Figure 2. Pedigrees of the families of the autosomal dominant AD cases and the familial cases in which a PS-1 mutation was observed. Probands were included in
the mutation analysis, except for families 1005 (III-20) and 1066 (V-2). Families 1061, 1069, 1072 and 1087 had not been included in our previous linkage studies
(20). Symbols: circles depict females, squares depict males; open symbols: unaffected individuals; filled symbols: AD patients; partly filled symbols: patients diagnosed
with CVA. Roman numbers to the left of the pedigree denote generations. Numbers below the patient symbols denote age at onset or age at death (). Arrows indicate
the probands. Patients that had autopsy confirmation of AD are indicated by an asterisk.
patient and an escapee. No other than the Ala79Val and
Tyr115Cys mutations in PS-1 were detected.
Segregation analysis
All six PS-1 mutations occurred in patients with a positive family
history of presenile AD, while the PS-2 mutation was observed
in a sporadic case (Table 2). Two PS-1 mutations were present in
autosomal dominant cases (1005 and 1066), while four PS-1
mutations were detected in familial cases (1061, 1069, 1072 and
1087) (Fig. 2). In the latter families the inheritance pattern was
consistent with autosomal dominant transmission (Fig. 2);
however, these families had not been selected for linkage studies
since they did not fulfil our rigid criteria for autosomal dominant
AD (1061, 1069 and 1087) or showed bilineal transmission of AD
(1072) (20). Only in family 1072 were additional family
members available and the PS-1 mutation Ala231Val was shown
to be present in at-risk individuals.
In autosomal dominant families 1005 and 1066 co-segregation
of the mutation with presenile AD was confirmed by restriction
enzyme digestion (Table 2 and Fig. 1A). Previously we had used
the informative families of the 10 autosomal dominant cases
included among the 101 cases in genetic linkage studies (20).
Family 1066 (mean onset age 42 years) was linked to D14S43
located at chromosome 14q24.3 [multipoint LOD score
(Z = 3.71) at zero recombination] (20). Family 1005 was not
informative for the chromosome 14 STR markers used.
DISCUSSION
Mutation analysis of all 10 coding exons as well as the
5′-non-coding exons of PS-1 and PS-2 by SSCP analysis and PCR
cycle sequencing identified four different missense mutations in
PS-1 in six patients (Ala79Val, Tyr115Cys, Ala231Val and
Glu318Gly) and one missense mutation in PS-2 in one other
patient (Arg62His) among 101 unrelated presenile AD cases in
our study. All but one of the mutations (7,27) are novel mutations
that were absent in 118 control individuals. Based on our mutation
data we calculated a mutation frequency of 6% for PS-1 and 1%
for PS-2 in presenile AD. Since all PS-1 mutations occurred in
familial cases, i.e. cases with at least one first degree relative with
AD, the mutation frequency is estimated at 9% (six out of 67
cases) in familial presenile AD cases. Among the familial cases
in our study there were 11 cases belonging to families fulfilling
our rigid criteria for autosomal dominant AD, i.e. three patients
in two generations with a clinical diagnosis of AD in at least two
cases (20). In two autosomal dominant families a PS-1 mutation
was found resulting in a mutation frequency of 18% (two out of
11 cases) in autosomal dominant presenile AD.
Since the mutation screening of PS-1 and PS-2 was performed
by SSCP analysis, we cannot exclude that our estimates of
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mutation frequencies of PS-1 and PS-2 are underestimates, as the
sensitivity of SSCP is not 100% (28). However, we systemati-
cally analyzed each PCR-amplified exon of PS-1 and PS-2
together with positive controls of known mutations in the
presence and absence of glycerol as denaturant. Mutations in
PS-1 and PS-2 may also have been masked by polymorphisms in
exonic and flanking intronic sequences. When polymorphic
SSCP patterns were observed we sequenced the PCR products in
five to 10 cases showing homozygous and heterozygous SSCP
patterns. In each case the underlying polymorphism was detected
and confirmed by restriction enzyme digestion of the amplified
product. The efficiency of our mutation analysis strategy is
demonstrated by detection of a mutation in exon 4 of PS-2 in one
patient that had a unique SSCP pattern different from that of the
polymorphic SSCP patterns observed for exon 4. Also, sequence
analysis of the polymorphic PCR products of exon 8 of PS-1
identified no mutations.
The onset age in the PS-1 mutation cases varied from 45 to 58
years, with three mutations (Ala79Val, Ala231Val and Glu318Gly)
having onset ages above 55 years (Table 2). Most PS-1 mutations
reported so far had onset ages between 35 and 55 years (29).
However, the majority of these mutations were located in exons
5 and 8, coding in part for TM II and the large HL after TM VI
(13). Here the mutations are predicted to interfere with the
α-helical structure of TM II or the proteolytic processing of ps-1
occurring in HL VI (7). The ps-1 mutations identified in this study
are located in the N-terminal region (Ala79Val in exon 4), in TM
V (Ala231Val in exon 7) and in the middle part of HL VI
(Glu318Gly in exon 9). Most likely these mutations have a milder
effect on ps-1 functioning, possibly because the amino acid
changes are semi-conserved (Ala79Val and Ala231Val) or they
are located in a functionally less important region (Glu318Gly).
The Glu318 mutation is located in a region of ps-1 that is less
conserved in ps-2 and ps of other species (13). Also, co-segrega-
tion of the Glu318Gly mutation with AD could not be demon-
strated, since no other relatives in family 1069 were available.
High variability in onset age was observed in PS-1 family 1005
segregating the Ala79Val mutation with a mean onset age in the
family of 64 years, ranging from 55 to 78 years. In one mutation
carrier the disease was not yet fully penetrant at age 76 years.
Possibly, the onset age in this family is modulated by other genetic
and/or environmental factors. In this respect it is important to note
that the non-penetrant case had an APOE ε3ε3 genotype, which
may have delayed his onset age (30). However, APOE studies in
larger samples of PS-1 cases and families are needed to conclude
that the APOE genotype modulates expression of PS-1 mutations.
Also, no effect of the APOE genotype on onset age was observed
in chromosome 14-linked AD families with PS-1 mutations,
leading to very early onset ages and severe phenotypes (31).
Another possibility is that the PS-1-linked phenotype is modu-
lated by a polymorphism in ps-2 or that mutations in ps-1 and ps-2
act together to express the disease phenotype (digenic effect).
However, SSCP analysis as well as RT-PCR analysis of PS-2
cDNA did not detect sequence alterations in ps-2. Family 1005 is
also of particular interest since in this family several patients had
been identified with cerebrovascular accidents (CVA) (Fig. 2).
However, none of them carried the PS-1 mutation, indicating that
the CVAs in this family are not related to presenile AD. In contrast
to the previous three PS-1 mutations, the Tyr115Cys mutation in
exon 5, corresponding to HL I, was detected in chromosome
14-linked family 1066, with mean onset age of 42 years (range
39–49 years) (20). The latter provides evidence that some of the
earlier mutation studies may indeed have been biased towards
finding PS-1 mutations resulting in earlier onset ages and more
severe phenotypes.
Only one PS-2 mutation, Arg62His, was observed in a sporadic
AD case with an onset age of 62 years. The two published PS-2
mutations had been identified in autosomal dominant families
with presenile AD in TM II and TM V of ps-2 (4,5). The mutated
Arg62 codon is not conserved in human ps-1 and ps of other
mammalian species and is located in a region of the N-terminal
domain that is generally not conserved between ps-1, ps-2 and the
Caenorhabditis elegans homolog sel-12 (32). Also, the mutation
itself is a conserved amino acid substitution. Therefore, it cannot
be excluded that this ps-2 mutation is a rare polymorphism not
related to AD pathogenesis, since the patient also had an APOE
ε3ε4 genotype which may have increased her risk of developing
AD (30).
In conclusion, our mutation data showed that PS-1 and PS-2
mutations are rare genetic causes of presenile AD in general.
Also, the frequency of PS-1 mutations in autosomal dominant AD
families (18%) is less frequent than initially estimated. No
mutations were identified in exons 16 and 17 of APP of any of the
cases (33), suggesting that other AD genes must exist. It is
possible that a fraction of the cases may be attributed to the
presence of an APOE ε4 allele. In a previous study of this
population-based sample we demonstrated that the risk for
developing presenile AD is significantly increased in APOE ε4
homozygotes independent of family history and in APOE ε4
heterozygotes in which the family history is positive (33). In the
sample of 101 cases there were 19 APOE ε4 homozygotes and 31
familial APOE ε4 heterozygotes.
In contrast to previous reports (29), we observed several PS-1
mutations leading to AD with onset ages above 55 years. Also,
one of these PS-1 mutations was identified in an autosomal
dominant family with a mean onset age of 64 years (range 55–78
years). The identification of these PS-1 mutations predicts that
PS-1 mutations with even milder effects on ps-1 functioning may
be present in senile AD. This is of particular importance since a
genetic association between an intronic PS-1 polymorphism and
senile AD has been reported (25), although this association could
not be replicated in all studies. Possibly, the association is the
result of a functionally more relevant sequence variation else-
where in the PS-1 gene. Preliminary data obtained by sequence
analysis failed to demonstrate sequence variations in the coding
region of PS-1 (25). However, the promoter and 5′-non-coding
region of PS-1 had not been examined, since these sequences
became available only recently. In this respect the identification
by us of two polymorphisms in the 5′-non-coding region of PS-1
is of interest, since these polymorphisms may be used in genetic
association studies to test whether PS-1 is also a susceptibility
gene for senile and/or presenile AD. Also, the intronic and exonic
polymorphisms identified in PS-2 are useful to test the role of this
gene in AD, an analysis that has not yet been performed.
MATERIALS AND METHODS
Subjects
All patients with a clinical diagnosis of AD and onset at or before
age 65 years, made in the period January 1980 and July 1987,
living in metropolitan Rotterdam and the four northern provinces
49
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were ascertained (18). The clinical diagnosis of AD was
independently confirmed by two neurologists using a standard-
ized protocol according to NINCDS-ADRDA criteria for AD
(34). A total of 198 patients participated in the study (18). Onset
age was defined as the age at which memory problems or
behavior changes were first noted. Cases were considered
familial when at least one first degree relative suffered from
dementia. The percentage of familial cases in the total sample of
presenile AD patients was 48% (18,33). Of familial cases the
pedigree was considered to segregate with autosomal dominant
AD if at least three patients with dementia were reported in two
generations and if there were at least two patients with detailed
medical records on the clinical diagnosis of AD (18,33).
Blood samples were drawn from 100 randomly selected AD
patients (33) and detailed data on family history of disease were
collected (18). Affected and unaffected relatives of 17 families
were visited at home, where blood was drawn. All relatives were
assessed for family history of disease, risk factors for AD and
memory performance (20). Blood samples were obtained from
118 control individuals matched for age within 5 years and place
of residence. The controls were drawn randomly from the
population register of the municipality of the patient (33).
Cognitive status of the control individuals was tested and none of
them showed symptoms of dementia at the time of the study.
Leukocytes were collected from total blood of the patients and
relatives and permanent lymphoblast cell lines were obtained by
transformation using Ebstein–Barr virus. DNA was extracted
from total blood or cultured lymphoblasts using a standard
phenol/chloroform DNA extraction procedure.
In our initial genetic analyses of the 100 cases we had included
nine autosomal dominant cases. However, recently an at-risk
individual in 1066 (V-2, Fig. 2) was diagnosed with probable AD
and included in this study, bringing the total number of cases to
101. Mutation analysis of exons 16 and 17 of APP excluded the
presence of APP mutations in all cases (33). The informative
families of 10 autosomal dominant cases were used in linkage
analysis studies with chromosome 14, 19 and 21 markers (20).
Family 1066 (mean onset age 42 years) was conclusively linked
to chromosome 14, while two others were excluded. The other
results were not informative. Since the linkage analysis studies
were performed before the presenile AD locus on chromosome
1 was identified, the families had not been analyzed for linkage
with chromosome 1 markers.
Polymerase chain reaction (PCR) analyses
About 200 ng DNA were amplified in a 25 µl reaction mixture
containing 20 pmol each primer, 0.2 mM dNTPs, 0.2 U Taq DNA
polymerase (Gibco-BRL, Gaithersburg, MD), 1.0 mM MgCl2,
75 mM Tris–HCl, pH 9.0, 20 mM (NH4)2SO4 and 0.01%
Tween-20. The PCR amplification consisted of 30 cycles of 90 s
at 94C, 90 s at the empirically defined optimal annealing
temperature and 90 s at 72C.
In the PCR–SSCP analyses intronic PCR primers were used to
amplify the exons and flanking intronic sequences of PS-1 and
PS-2 (Table 1). The PCR amplification products were heat
denatured, cooled on ice and separated using two different
electrophoresis systems. The coding exons of PS-1 were analyzed
on a 1× HydroLink MDE gel (J.T.Baker, Phillipsburg) with and
without 10% glycerol. Electrophoresis was for 20 h at 800 V and
at 4C (with glycerol) or room temperature (without glycerol).
The SSCP/heteroduplex patterns were visualized using silver
staining. Alternatively, the non-coding exons of PS-1 and all
exons of PS-2 were analyzed on a MultiPhorII electrophoresis
system (Pharmacia Biotech, Uppsala, Sweden) using ExcellGel
precast polyacrylamide gels and 1× HydroLink MDE gels
containing 5% glycerol. Electrophoresis was at 600 V for 2–5 h,
depending on the product sizes, and SSCP patterns were
visualized using silver staining. SSCP analyses of exons 5–8, and
11 of PS-1 were performed in the presence of positive control
samples of the Ile143Thr, Met146Leu, His163Arg, Ala246Glu,
Leu286Val, Gly384Ala and Cys410Tyr mutations (3,23). When
aberrant SSCP patterns were observed the sequences of the
fragments were determined using cycle sequencing. The PCR
amplification products were pretreated with 10 U exonuclease I
and 2 U shrimp alkaline phosphatase to remove excess PCR
primers and nucleotides. PCR amplification product (5 µl) was
used as template in the cycle sequencing reaction using the ABI
PRISM Dye Terminator Cycle Sequencing Core Kit (Applied
Biosystems, Foster City, CA) according to the supplier’s
protocol, using the same primers as in the PCR amplification. The
sequences were analyzed on an ABI 373A automated DNA
sequencer.
Sequence variations in PS-1 and PS-2 were analyzed by
restriction enzyme digestion of amplified products when they
involved the creation or abolition of a restriction enzyme
recognition site. Also, the intron 8 polymorphism in PS-1 was
analyzed by BamHI digestion as described (25). Genomic PCR
amplification products were digested for 3 h using 5 U of the
corresponding restriction enzyme (Tables 2 and 3) at the
appropriate reaction temperature. The restriction fragments were
separated on a 1.5–3% agarose gel, depending on the allele sizes,
and visualized on an UV transilluminator after EtBr staining.
The APOE genotype was scored by PCR amplification of
genomic DNA using published primers (35) in a standard PCR of
35 cycles. After digestion with 5 U HhaI for 3 h at 37C the alleles
were separated on ExcellGel precast polyacrylamide gels as
described above and visualized using silver staining.
The STRs D14S1028, D14S77 and D14S1008 were amplified
in a standard PCR using published primer sets, one of which was
fluorescently labeled. The alleles were separated on a 6%
polyacrylamide gel containing 8 M urea and analyzed on an ABI
373A automated DNA sequencer using GENESCAN 672
software (Applied Biosystems).
cDNA sequence analysis
Approximately 107 lymphoblast cells were homogenized in the
presence of 1 ml TRIzol (Gibco-BRL). RNA was isolated by
chloroform extraction and precipitated with isopropanol. After
centrifugation for 10 min in a microfuge, the pellet was washed
with 75% EtOH and dissolved in 20 µl DEPC-treated H2O. First
strand cDNA synthesis was performed with random primers using
the SuperScript pre-amplification kit (Gibco-BRL) as described in
the protocol supplied with the kit. The RNA was removed by
adding 2 U RNase H and incubating for 20 min at 37C. A standard
PCR amplification of 30 cycles was performed using 100 ng first
strand cDNA as template. Then PS-1 cDNA was PCR amplified
using primer pairs 917/892, 901/111R and 1017/852 (3). The
sequence of the amplification products was determined by cycle
sequencing as described above. Sequencing primers were as
published (3,23). PS-2 cDNA was PCR amplified using primer
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pairs STM2-6/7 (5′-AACCAGCGCTGCCCTCTTTGAA-3′ and
5′-AGGATGACCCACGCGGACCACTC-3′) and STM2-8/9
(5′-CTACCCCACCCTCTTGCTGACTGT-3′ and 5′-CTCCCC-
GCCCTAATCTGACCTTCT-3′). Cycle sequencing was performed
using the same primers, primer 1021 (5) (5′-CAGAGGATGGA-
GAGAACAC-3′), STM2-6 (5′-AACCAGCGCTGCCCTCTT-
TGAA-3′), STM2-1 (5′-ATCGTGGTGGTAGCC-3′), STM2-2
(5′-GTTATGACCATCTTCTTGG-3′), STM2-4 (5′-TGTGCTGT-
GTCCCAAAGG-3′) and PS2-1742AS (5′-TCCAATGAAAATT-
CCCTGC-3′). The sequence of the PS-2 cDNA was determined by
cycle sequencing as described above.
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